ADVFN Logo

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

MRK Merck and Co Inc

128,03
-0,16 (-0,12%)
Zuletzt aktualisiert: 17:20:30
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Merck and Co Inc MRK NYSE Common Stock
  Änderung Änderung % Aktuell Zeit
-0,16 -0,12% 128,03 17:20:30
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
128,38 127,42 128,8525 128,19
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
27.2.202412:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23.2.202412:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20.2.202422:14EDGAR2Form 8-K - Current report
20.2.202412:45BWFDA Grants Priority Review to Merck's Application for..
15.2.202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:40EDGAR2Form 144 - Report of proposed sale of securities
14.2.202422:30EDGAR2Form 144 - Report of proposed sale of securities
14.2.202422:24EDGAR2Form 144 - Report of proposed sale of securities
13.2.202422:50EDGAR2Form 144 - Report of proposed sale of securities
13.2.202422:48EDGAR2Form 144 - Report of proposed sale of securities
12.2.202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202413:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..
09.2.202422:06EDGAR2Form 144 - Report of proposed sale of securities
08.2.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.2.202413:00PRNCAMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE..
07.2.202422:09EDGAR2Form 144 - Report of proposed sale of securities
05.2.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202412:33PRNUSElanco Announces Sale of Aqua Business for $1.3 Billion
02.2.202422:35EDGAR2Form 144 - Report of proposed sale of securities
02.2.202422:09EDGAR2Form 144 - Report of proposed sale of securities
02.2.202422:08EDGAR2Form 144 - Report of proposed sale of securities
02.2.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202412:39EDGAR2Form 8-K - Current report
01.2.202412:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27.1.202416:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26.1.202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26.1.202416:00BWMerck’s KEYTRUDA® (pembrolizumab) Significantly Improved..
25.1.202414:07DJNLava Therapeutics Shares Rise as Drug Set for Test With..
24.1.202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.1.202421:29EDGAR2Form SC 13G - Statement of acquisition of beneficial..
23.1.202420:44BWMerck Announces Second-Quarter 2024 Dividend
23.1.202412:05DJNSanofi to Buy Assets From Inhibrx in Deal Valued at Up to..
19.1.202412:45BWMerck to Hold Fourth-Quarter and Full-Year 2023 Sales and..
15.1.202414:15PRNUSMerck Animal Health's Fourth Veterinary Wellbeing Study..
13.1.202400:13DJNMerck's Keytruda Combined with Chemoradiotherapy Gets FDA..
12.1.202423:30BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
09.1.202416:21DJNMerck on Track for Record High Close -- Data Talk
09.1.202412:12IHMARKETNEWSWall Street Highlights: HPE and Juniper Networks in..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

Support: +44 (0) 203 8794 460 | support@advfn.de